WO2001021136A2 - Compositions and methods for improved detection and classification of neoplasms - Google Patents
Compositions and methods for improved detection and classification of neoplasms Download PDFInfo
- Publication number
- WO2001021136A2 WO2001021136A2 PCT/US2000/026105 US0026105W WO0121136A2 WO 2001021136 A2 WO2001021136 A2 WO 2001021136A2 US 0026105 W US0026105 W US 0026105W WO 0121136 A2 WO0121136 A2 WO 0121136A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- specific binding
- transcription factor
- sample
- composition
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 192
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 183
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000001514 detection method Methods 0.000 title description 20
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 269
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 269
- 230000009870 specific binding Effects 0.000 claims abstract description 196
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 238000012360 testing method Methods 0.000 claims abstract description 111
- 238000011282 treatment Methods 0.000 claims abstract description 77
- 201000011510 cancer Diseases 0.000 claims abstract description 71
- 238000009739 binding Methods 0.000 claims abstract description 69
- 230000027455 binding Effects 0.000 claims abstract description 65
- 230000036210 malignancy Effects 0.000 claims abstract description 64
- 208000035269 cancer or benign tumor Diseases 0.000 claims abstract description 57
- 239000000523 sample Substances 0.000 claims description 173
- 239000000126 substance Substances 0.000 claims description 51
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 210000001519 tissue Anatomy 0.000 claims description 40
- 101710099061 Myogenic factor 5 Proteins 0.000 claims description 30
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 30
- 239000007787 solid Substances 0.000 claims description 30
- 102100032970 Myogenin Human genes 0.000 claims description 27
- 230000003211 malignant effect Effects 0.000 claims description 27
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 26
- 108010056785 Myogenin Proteins 0.000 claims description 24
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 claims description 20
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 claims description 20
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 claims description 20
- 102100038313 Transcription factor E2-alpha Human genes 0.000 claims description 19
- -1 TC Ralpha/delta Proteins 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 17
- 239000003937 drug carrier Substances 0.000 claims description 12
- 230000001114 myogenic effect Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 claims description 8
- 101000610107 Homo sapiens Pre-B-cell leukemia transcription factor 1 Proteins 0.000 claims description 8
- 101000610110 Homo sapiens Pre-B-cell leukemia transcription factor 2 Proteins 0.000 claims description 8
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 claims description 8
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 claims description 8
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 claims description 8
- 102100040171 Pre-B-cell leukemia transcription factor 1 Human genes 0.000 claims description 8
- 102100040168 Pre-B-cell leukemia transcription factor 2 Human genes 0.000 claims description 8
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 8
- 102100023876 Rhombotin-2 Human genes 0.000 claims description 8
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 claims description 8
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 208000005927 Myosarcoma Diseases 0.000 claims description 6
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 claims description 5
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 claims description 5
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims description 5
- 101150047137 ABF1 gene Proteins 0.000 claims description 4
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 claims description 4
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 claims description 4
- 102100037676 CCAAT/enhancer-binding protein zeta Human genes 0.000 claims description 4
- 101710104127 CCAAT/enhancer-binding protein zeta Proteins 0.000 claims description 4
- 101150031329 Ets1 gene Proteins 0.000 claims description 4
- 102100024001 Hepatic leukemia factor Human genes 0.000 claims description 4
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 claims description 4
- 101100025200 Homo sapiens MSC gene Proteins 0.000 claims description 4
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 claims description 4
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 claims description 4
- 101000909637 Homo sapiens Transcription factor COE1 Proteins 0.000 claims description 4
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 claims description 4
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims description 4
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims description 4
- 101100351501 Mus musculus Cbfb gene Proteins 0.000 claims description 4
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 claims description 4
- 102100038169 Musculin Human genes 0.000 claims description 4
- 101100438011 Oryza sativa subsp. japonica BZIP12 gene Proteins 0.000 claims description 4
- 102100030798 Transcription factor HES-1 Human genes 0.000 claims description 4
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 claims description 4
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 108010006693 promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein Proteins 0.000 claims description 4
- 210000004872 soft tissue Anatomy 0.000 claims description 4
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 claims description 3
- 102100036639 Myosin-11 Human genes 0.000 claims description 3
- 201000002077 muscle cancer Diseases 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 101000912957 Homo sapiens Protein DEK Proteins 0.000 claims description 2
- 239000013068 control sample Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 239
- 230000000694 effects Effects 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 150000007523 nucleic acids Chemical class 0.000 description 34
- 201000010099 disease Diseases 0.000 description 33
- 230000004069 differentiation Effects 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 108091033319 polynucleotide Proteins 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 28
- 108020004707 nucleic acids Proteins 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000012530 fluid Substances 0.000 description 14
- 210000004408 hybridoma Anatomy 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 208000006168 Ewing Sarcoma Diseases 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 13
- 210000003098 myoblast Anatomy 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000000975 bioactive effect Effects 0.000 description 11
- 230000031018 biological processes and functions Effects 0.000 description 11
- 210000005170 neoplastic cell Anatomy 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 239000013592 cell lysate Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000011132 hemopoiesis Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000020509 sex determination Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 101150039183 MYF6 gene Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100038379 Myogenic factor 6 Human genes 0.000 description 6
- 101150108975 Rhd gene Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000010827 pathological analysis Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 231100000027 toxicology Toxicity 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000001272 neurogenic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 230000002110 toxicologic effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102100036912 Desmin Human genes 0.000 description 4
- 108010044052 Desmin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 210000005045 desmin Anatomy 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 231100000723 toxicological property Toxicity 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 101000589002 Homo sapiens Myogenin Proteins 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108700001591 MyoD Proteins 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229930185229 antidesmin Natural products 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 201000007455 central nervous system cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000637851 Homo sapiens Tolloid-like protein 1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100031996 Tolloid-like protein 1 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003540 anti-differentiation Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- 101100468581 Arabidopsis thaliana RH28 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001092081 Carpenteria Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000010091 Cold shock domains Human genes 0.000 description 1
- 108050001774 Cold shock domains Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000040848 ETS family Human genes 0.000 description 1
- 108091071901 ETS family Proteins 0.000 description 1
- 101150025421 ETS gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000049983 HMGA1a Human genes 0.000 description 1
- 108700039142 HMGA1a Proteins 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101001012669 Homo sapiens Melanoma inhibitory activity protein 2 Proteins 0.000 description 1
- 101000958865 Homo sapiens Myogenic factor 5 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102100029778 Melanoma inhibitory activity protein 2 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 102100032062 Neurogenic differentiation factor 2 Human genes 0.000 description 1
- 108050000625 Neurogenic differentiation factor 2 Proteins 0.000 description 1
- 102100038550 Neurogenin-1 Human genes 0.000 description 1
- 101710096136 Neurogenin-1 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700040013 TEA Domain Transcription Factors Proteins 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the ability to accurately diagnose neoplasms is central to the successful treatment and subsequent survivability and quality of life of those fallen victim to cancer.
- the penalty for error in such diagnosis is high for the patient. For example, if a malignant growth is improperly diagnosed as benign, then the patient has poor prognosis compared to patients accurately diagnosed and correctly treated.
- a benign growth is diagnosed as malignant, then the patent may be subjected to unnecessary and costly treatments that themselves can be life threatening.
- FIG. 1 depicts a western blot analysis of myogenin in various small round cell tumor cell lines using the F5D monoclonal antibody. That antibody only detectably binds with a band corresponding to the molecular size of myogenin (approximately 34 kd) in the Rh30 rhabdomyosarcoma cell lysate. All other small round cell tumor lysates did not detectably bind with that antibody.
- Rh30 Rhabdomyosarcoma cell line
- PFSK-1 A Primitive neuroectoderal tumor cell line
- EB2 Lymphoma cell line
- SKNSH Neuroblastoma cell line
- SJSA-1 Ewing's sarcoma cell line.
- FIG. 1 depicts a western blot analysis of myogenin in various small round cell tumor cell lines using the F5D monoclonal antibody. That antibody only detectably binds with a band corresponding to the molecular size of myogenin (approximately 34
- FIG. 2A and FIG. 2B depict the predicted patient survival by the Kaplan and Meier analysis based on conventional histological classification versus antibody based subclassification for myogenin and myf5 expression in tumor cells.
- This type of analysis is based on the finding that tumors erroneously subclassified as embryonal or alveolar rhabdomyosarcoma will cause the difference in survival between the two groups (projected survival curves for embryonal and alveolar rhabdomyosarcoma) to be less significant (FIG. 2A).
- a highly significant difference in survival between the embryonal and alveolar rhabdomyosarcoma that has been subclassified by anti-myf5 and anti-myogenin antibody typing is expected (FIG. 2B).
- a first aspect of the present invention is composition including at least two different specific binding members that can specifically bind with at least two different transcription factors.
- a third aspect of the present invention is a method for identifying a test compound that modulates a neoplasm such as a malignancy including contacting a sample with at least one test compound, contacting said sample with at least one specific binding member that can bind with at least one transcription factor, and detecting the binding of said at least one specific binding member with at least one transcription factor.
- a fifth aspect of the present invention is a method for distinguishing between clinically distinct subtypes of neoplasms such as malignancy including contacting at least one specific binding member that can specifically bind with a transcription factor with a sample, and detecting the binding of said at least one specific binding member with a transcription factor in said sample.
- a sixth aspect of the present invention is a monoclonal antibody that specifically binds with a member of the MyoD family of transcription factors, a leukemic transcription factor, a sex determination transcription factor or a hematopoiesis transcription factor.
- Such monoclonal antibody can optionally be detectably labeled.
- hydrophilic groups are masked to provide more hydrophobic derivatives.
- the making groups can be designed to be cleaved from the compound within a cell to make the compound more hydrophilic once within the cell. Because the substrate is more hydrophilic than the membrane permeant derivative, it preferentially localizes within the cell
- isolated polynucleotide refers to a polynucleotide of genomic, cDNA, or synthetic origin, or some combination thereof, which by virtue of its origin, the isolated polynucleotide (1) is not associated with the cell in which the isolated polynucleotide is found in nature, or (2) is operably linked to a polynucleotide that it is not linked to in nature.
- the isolated polynucleotide can optionally be linked to promoters, enhancers, or other regulatory sequences.
- Polypeptide is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence.
- Active fragment refers to a fragment of a parent molecule, such as an organic molecule, nucleic acid molecule, or protein or polypeptide, or combinations thereof, that retains at least one activity of the parent molecule.
- Operaably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
- a control sequence operably linked to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
- Control sequences refer to polynucleotide sequences that affect the expression of coding and non-coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal biding site, and transcription termination sequences; in eukaryotes, generally, such control sequences include promoters and transcription termination sequences.
- the term control sequences is intended to include components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
- Polynucleotide refers to a polymeric form of nucleotides of a least ten bases in length, either ribonucleotides or deoxynucleotides or a modified from of either type of nucleotide.
- the term includes single and double stranded forms of DNA or RNA.
- Genomic polynucleotide refers to a portion of the genome.
- Active genomic polynucleotide or “active portion of a genome” refers to regions of a genome that can be up regulated, down regulated or both, either directly or indirectly, by a biological process.
- Directly in the context of a biological process or processes, refers to direct causation of a process that does not require intermediate steps, usually caused by one molecule contacting or binding to another molecule (the same type or different type of molecule). For example, molecule A contacts molecule B, which causes molecule B to exert effect X that is part of a biological process.
- Sequence homology refers to the proportion of base matches between two nucleic acid sequences or the proportion of amino acid matches between two amino acid sequences. When sequence homology is expressed as a percentage, for example 50%, the percentage denotes the proportion of matches of the length of sequences from a desired sequence that is compared to some other sequence. Gaps (in either of the two sequences) are permitted to maximize matching; gap lengths of 15 bases or less are usually used, 6 bases or less are preferred with 2 bases or less more preferred.
- Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred.
- a reference sequence is a defined sequence used as a basis for a sequence comparison; a reference sequence can be a subset of a larger sequence, for example, as a segment of a full length cDNA or gene sequence given in a sequence listing, or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length.
- Sequence identity means that two polynucleotide sequences are identical (for example, on a nucleotide-by-nucleotide basis) over the window of comparison.
- Percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (for example, the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- Substantial identity denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 30 percent sequence identity, preferably at least 50 to 60 percent sequence, more usually at least 60 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 25 to 50 nucleotides, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence that may include deletions or addition which total 20 percent or less of the reference sequence over the window of comparison.
- Substantial identity as applied to polypeptides herein means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 30 percent sequence identity, preferably at least 40 percent sequence identity, and more preferably at least 50 percent sequence identity, and most preferably at lest 60 percent sequence identity.
- residue positions which are not identical, differ by conservative amino acid substitutions.
- Constant amino acid substitutions refer to the interchangeability of residues having similar side chains.
- a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine and tryptophan; a group of amino acids having basic side chains is lysine, arginine and histidine; and a group of amino acids having sulfur-containing side chan is cystein and methionine.
- Preferred conservative amino acid substitution groups are: valine-leucine- isoleucine; phenylalanine-tyrosine; lysine-arginine; alanine-valine; glutamate-aspartate; and asparagine-glutamine.
- “Modulation” refers to the capacity to either enhance or inhibit a functional property of a biological activity or process, for example, enzyme activity or receptor binding. Such enhancement or inhibition may be contingent on the occurrence of a specific event, such as activation of a signal transduction pathway and/or may be manifest only in particular cell types.
- Module refers to a chemical (naturally occurring or non-naturally occurring), such as a biological macromolecule (for example, nucleic acid, protein, non-peptide or organic molecule) or an extract made from biological materials, such as prokaryotes, bacteria, eukaryotes, plants, fungi, multicellular organisms or animals, invertebrates, vertebrates, mammals and humans, including, where appropriate, extracts of: whole organisms or portions of organisms, cells, organs, tissues, fluids, whole cultures or portions of cultures, or environmental samples or portions thereof.
- a biological macromolecule for example, nucleic acid, protein, non-peptide or organic molecule
- an extract made from biological materials such as prokaryotes, bacteria, eukaryotes, plants, fungi, multicellular organisms or animals, invertebrates, vertebrates, mammals and humans, including, where appropriate, extracts of: whole organisms or portions of organisms, cells, organs, tissues, fluids, whole cultures or portions of cultures, or environmental samples
- Modulators are typically evaluated for potential activity as inhibitors or activators (directly or indirectly) of a biological process or processes (for example, agonist, partial antagonist, partial agonist, antagonist, antineoplastic, cytotoxic, inhibitors of neoplastic transformation or cell proliferation, cell proliferation promoting agents, antiviral agents, antimicrobial agents, antibacterial agents, antibiotics, and the like) by inclusion in assays described herein.
- a biological process or processes for example, agonist, partial antagonist, partial agonist, antagonist, antineoplastic, cytotoxic, inhibitors of neoplastic transformation or cell proliferation, cell proliferation promoting agents, antiviral agents, antimicrobial agents, antibacterial agents, antibiotics, and the like.
- the activity of a modulator may be known, unknown or partially known.
- Test chemical refers to a chemical, composition or extract to be tested by at least one method of the present invention to be a putative modulator.
- a test chemical can be of any chemical composition, such as inorganic, organic or a biomolecule.
- a biomolecule can be any molecule of biological origin that is found in or produced at least in part by a cell, and include, but are not limited to polypeptides, nucleic acids, lipids, carbohydrates or combinations thereof.
- a test chemical is usually not known to bind to the target of interest.
- Control test chemical refers to a chemical known to bind to the target (for example, a known agonist, antagonist, partial agonist or inverse agonist).
- Test chemical does not typically include a chemical added to a mixture as a control condition that alters the function of the target to determine signal specificity in an assay.
- control chemicals or conditions include chemicals that (1) non-specifically or substantially disrupt protein structure (for example denaturing agents such as urea or guandium, sulfhydryl reagents such as dithiotritol and beta-mercaptoethanol), (2) generally inhibit cell metabolism (for example mitochondrial uncouples) and (3) non-specifically disrupt electrostatic or hydrophobic interactions of a protein (for example, high salt concentrations or detergents at concentrations sufficient to non-specifically disrupt hydrophobic or electrostatic interactions).
- non-specifically or substantially disrupt protein structure for example denaturing agents such as urea or guandium, sulfhydryl reagents such as dithiotritol and beta-mercaptoethanol
- cell metabolism for example mitochondrial uncouples
- non-specifically disrupt electrostatic or hydrophobic interactions of a protein for example, high salt concentrations or detergent
- test chemical also does not typically include chemicals known to be unsuitable for a therapeutic use for a particular indication due to toxicity of the subject.
- various predetermined concentrations of test chemicals are used for determining their activity. If the molecular weight of a test chemical is known, the following ranges of concentrations can be used: between about 0.001 micromolar and about 10 millimolar, preferably between about 0.01 micromolar and about 1 millimolar, more preferably between about 0.1 micromolar and about 100 micromolar.
- concentration of test chemical used can be expressed on a weight to volume basis.
- the following ranges of concentrations can be used: between about 0.001 micrograms/ml and about 1 milligram/ml, preferably between about 0.01 micrograms/ml and about 100 micrograms/ml, and more preferably between about 0.1 micrograms/ml and about 10 micrograms/ml.
- Target refers to a biochemical entity involved in a biological process. Targets are typically proteins that play a useful role in the physiology or biology of an organism. A therapeutic chemical typically binds to a target to alter or modulate its function. As used herein, targets can include, but not be limited to, cell surface receptors, G-proteins, G-protein coupled receptors, kinases, phosphatases, ion channels, Upases, phosholipases, nuclear receptors, intracellular structures, transcription factors, tubules, tubulin, and the like.
- Label refers to incorporation of a detectable marker, for example by incorporation of a radiolabled compound or attachment to a polypeptide of moieties such as biotin that can be detected by the binding of a section moiety, such as marked avidin.
- a detectable marker for example by incorporation of a radiolabled compound or attachment to a polypeptide of moieties such as biotin that can be detected by the binding of a section moiety, such as marked avidin.
- Various methods of labeling polypeptide, nucleic acids, carbohydrates, and other biological or organic molecules are known in the art.
- Such labels can have a variety of readouts, such as radioactivity, fluorescence, color, chemiluminescence or other readouts known in the art or later developed.
- the readouts can be based on enzymatic activity, such as beta-galactosidase, beta-lactamase, horseradish peroxidase, alkaline phosphatase, luciferase; radioisotopes such as 3 H, 14 C, 35 S, 125 I or 131 I); fluorescent proteins, such as green fluorescent proteins; or other fluorescent labels, such as FITC, rhodamine, and lanthanides. Where appropriate, these labels can be the product of the expression of reporter genes, as that term is understood in the art. Examples of reporter genes are beta-lactamase (U.S. Patent No. 5,741,657 to Tsien et al., issued April 21, 1998) and green fluorescent protein (U.S. Patent No. 5,777,079 to Tsien et al., issued July 7, 1998; U.S. Patent No. 5,804,387 to Cormack et al., issued September 8, 1998).
- enzymatic activity such as beta-galact
- substantially pure refers to an object species or activity that is the predominant species or activity present (for example on a molar basis it is more abundant than any other individual species or activities in the composition) and preferably a substantially purified fraction is a composition wherein the object species or activity comprises at least about 50 percent (on a molar, weight or activity basis) of all macromolecules or activities present.
- substantially pure composition will comprise more than about 80 percent of all macromolecular species or activities present in a composition, more preferably more than about 85%, 90%, 95% and 99%.
- the object species or activity is purified to essential homogeneity, wherein contaminant species or activities cannot be detected by conventional detection methods) wherein the composition consists essentially of a single macromolecular species or activity.
- an activity may be caused, directly or indirectly, by a single species or a plurality of species within a composition, particularly with extracts.
- “Pharmaceutical agent or drug” refers to a chemical, composition or activity capable of inducing a desired therapeutic effect when property administered by an appropriate dose, regime, route of administration, time and delivery modality.
- a “bioactive compound” refers to a compound that exhibits at least one bioactivity, including but not limited to antiviral activity, antineoplastic activity, antitumor activity, anticancer cell activity, differentiation activity, anti-differentiation activity and cytotoxicity.
- a “bioactivity” refers to a composition that exhibits at least one bioactivity.
- bioactive derivative refers to a modification of a bioactive compound or bioactivity that retains at least one characteristic bioactivity of the parent compound.
- bioactive precursor refers to a precursor of a bioactive compound or bioactivity that exhibits at least one characteristic activity of the resulting bioactive compound or bioactivity.
- an "antineoplastic activity” refers to an activity that reduces the growth rate or number of neoplastic cells in a sample, such as a culture of cancer cells or a sample that includes at least one neoplastic cell, including a patient.
- a sample such as a culture of cancer cells or a sample that includes at least one neoplastic cell, including a patient.
- Such antineoplastic activity can be directed against any type of neoplasms, including, but not limited to renal cancer, leukemia, lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer and breast cancer.
- an “anticancer cell activity” refers to an activity that reduces the growth rate or number of cancer cells in a sample, such as a culture of cancer cells or a sample that includes at least one cancer cell, including a patient. Such anticancer cell activity can be directed against any type of cancer cell, including, but not limited to renal cancer, leukemia, lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, breast cancer, soft tissue cancers and bone cancer.
- an “antitumor activity” refers to an activity that reduces the growth rate or number of tumor cells in a sample, such as a culture of tumor cells or a sample that includes at least one tumor cell, including a patient. Such antitumor activity can be directed against any type of tumor or tumor cell, including, but not limited to renal tumor, lung tumor, colon tumor, central nervous system tumor, melanoma, ovarian tumor, breast tumor, soft tissue and bone.
- a “differentiation activity” refers to an activity that promotes a greater degree of differentiation of a cell.
- An “anti-differentiation activity” refers to an activity that promotes a lesser degree of differentiation of a cell.
- a "cytotoxic activity” refers to an activity that reduces the number of viable cells in a sample, including prokaryotic cells, eukaryotic cells or both.
- a “subject” or “patient” refers to a whole organism in need of treatment, such as a farm animal, companion animal or human.
- An “animal” refers to a non-human animal.
- a “treatment” refers to a treatment for a disease state, such as a neoplasm such as a malignancy.
- a treatment can include chemicals, such as chemotherapeutic agents or test compounds and/or non-chemical treatment, such as electrical pules (such as electroinnovation), magnetic fields or radiation (such as radiation therapy) (see, for example, Buonanno et al., Nucleic Acids Res. 20:539-544 (1992)).
- a “specific binding member” refers to a member of a group of two or moieties that can specifically bind with each other rather than becoming non-specifically associated with each other, such as by precipitation.
- specific binding members include, but are not limited to, antigen-antibody, receptor-ligand and nucleic acid-nucleic acid pairs.
- Specific,” “specifically,” “specifically bind” or a “specific binding reaction” in the context of the binding of first specific binding member with at least one other specific binding member refers to binding that is preferential and not non-specific. Preferably, a specific binding reaction is unique for the specific binding members, but that need not be the case.
- Detectably bind refers to the specific binding of one specific binding member with at least one other specific binding member that can be detected.
- one specific binding member can be detectably labeled such that the detectable presence of the label indicates a specific binding event.
- the detection limits of such detectable binding are related to the detectable label used and the detection method or device used.
- an “antibody” refers to an immunoglobulin of any class or subclass, a portion thereof or an active fragment thereof, wherein an active fragment of an antibody retains its specific binding capability.
- An antibody can be a polyclonal antibody, a monoclonal antibody or a mixture thereof.
- a “cellular component” refers to a portion of a cell, such as an organelle or other structure, or protein or other biomolecule, that is on or within a cell.
- a “transcription factor” refers to a molecule that can modulate the expression or transcription of a gene or nucleic acid sequence. Such transcription factors are known in the art, such as those described in http://transfac.gbf-braunschweig.de/TRANSFAC/cl/cl.html (February 17, 1999).
- Transcription factors include, but are not limited to, leucine zipper factors, helix- loop-helix factors, basic-helix-loop-helix factors, helix-loop-helix/leucine zipper factors, NF-1 factors, RF-X factors, bHSH factors, Cys4 zinc finger of nuclear receptor factors, diverse Cys4 zinc finger factors, Cys2His2 zinc finger factors, Cys6 cystein-zinc cluster factors, Homeo domain factors, paired box factors, fork head/winged helix factors, heat shock factors, tryptophane cluster factors, TEA domain factors, RHR factors, p53 factors, MADS box factors, beta-barrel alpha-helix factors, TATA-binding factors, HMG factors, heteromeric CCAAT factors, Grainyhead factors, cold-shock domain factors, Runt factors, copper fist factors, HMGI(Y) factors, STAT factors and pocket domain factors. See, for example, Littlewood and Evan, Helix-Loop-Helix Tra
- myogenic transcription factor refers to a factor that regulates expression of muscle specific genes and other genes associated with the muscle differentiation program, which includes but is not limited to the MyoD family of transcription factors, which includes but is not limited to myf5, MyoD (also known as my ⁇ ), myogenin (also known as myf4) or myf6.
- a “leukemic transcription factor” refers to a factor that regulates expression of lymphocyte specific genes and other genes associated with the lymphocyte differentiation program, which includes but is not limited to E2A, PBX1, RBTN2, TC Ralpha/delta, PBX2, E2A, HLF, AML1 , ETO, PML-RARalpha S, S/F forms, TEL, BCR, ABL, ALL, MYH11 ,
- a “neurogenic transcription factor” refers to a factor that regulates expression of neurogenic specific genes and other genes associated with the neurogenic differentiation program, such as those described in Littlewood and Evan, supra, 1998.
- a “sex determination transcription factor” refers to a factor that regulates expression of sex determination specific genes and other genes associated with sex determination programs, such as those described in Littlewood and Evan, supra, 1998.
- hematopoiesis transcription factor refers to a factor that regulates expression of hematopoiesis specific genes and other genes associated with the hematopoiesis differentiation program, such as those described in Littlewood and Evan, supra, 1998.
- Immobilized such as “immobilized on a solid support” refers to a moiety, such as a macromolecule, such as a protein, or a cell, that has been either reversibly or irreversibly localized.
- a moiety such as a protein can be irreversibly immobilized on a solid support by a variety of methods known in the art, such as by cross-linking with glutaraldehyde or other appropriate chemicals.
- a moiety such as an antigen can be reversibly immobilized by being attached to, for example, a specific binding member that is immobilized on a solid support.
- a solid support can be coated with a compound such that the solid support irreversibly or reversibly immobilizes a moiety.
- a glass or plastic surface can be coated with fibronectin, which promotes the reversible immobilization of a eukaryotic cell on the solid support.
- a “solid support” refers to any solid substrate in any form.
- a solid support can be a plastic (such as polystyrene or cycloolefin polymers) a glass, a magnetic compound, a membrane (such as nylon or nitrocellulose) or other appropriate solid substrate for a particular application.
- a solid support can take any configuration, such as beads, sheets, tubes, plates and/or wells (such as microtiter plates), circle or columns or other configuration appropriate for a particular application.
- Neoplasm refers to a cell or a population of cells, including a tumor or tissue (including cell suspensions such as bone marrow and fluids such as blood or serum), that exhibits abnormal growth by cellular proliferation greater than normal tissue. Neoplasms can be benign or malignant.
- a "benign cell” refers to a non-malignant neoplasm.
- a "malignant cell” or a “malignancy” refers to a cell that is abnormal and can be classified as a malignancy.
- a malignant cell can be capable of metastasis under appropriate conditions.
- a malignancy can have a variety of subtypes, including clinically distinct subtypes, such as, for example, alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma, which have different prognoses and different responses to therapies.
- a “soft malignant cell” or “soft tissue malignant cell” refers to a cell from malignancies from a solid tissue (as opposed to blood cells), excluding bone.
- a “solid malignant cell” refers to a cell from a malignancy from a sold tissue, including the bone.
- myosarcoma refers to a malignant neoplasm derived from muscular tissue.
- rhabdomyosarcoma refers to a malignant neoplasm that exhibit myogenic features that can occur in the skeletal muscle, brain, heart, lung, kidney, bladder, vagina and other locations in the body.
- Alveolar rhabdomyosarcoma refers to a rhabdomyosarcoma that shows reciprocal translocations involving chromosome 12 and 13.
- Embryonal rhabdomyosarcoma refers to a rhabdomyosarcoma that frequently show deletion of chromosome l ip.
- a "tissue” refers to a collection of cells as that term is known in the art.
- a "culture” of cells is a collection of cells as that term is known in the art and can be a clonal population of cells or a mixed population of cells.
- a "tumor tissue” is a collection of cells that includes at least one cell derived from at least one tumor.
- a “fixed tissue” is a tissue that has been fixed for evaluation, staining or viewing using a variety of methods known in the art, such as by treatment with paraformaldehyde, formaldehyde, acetone, methanol or a combination thereof.
- a “cell extract” refers to a preparation that is derived from least one cell from at least one source of cells, such as from a tissue or from culture, that has been treated such that at least one cellular component of the source of cells is no longer in its natural cellular environment.
- cell extracts can be made by rupturing cells using methods known in the art.
- a “sample” includes any physical sample that includes a cell or a cell extract from a cell.
- a sample can be from a biological source such as a subject or animal or a portion thereof, or from a cell culture.
- Samples from a biological source can be from a normal or abnormal organism (such as an organism suffering from a condition or disease state, such as a neoplasm) or portion thereof and can be from any fluid, tissue or organ, including healthy or abnormal (such as diseased or neoplastic) fluids, tissues or organs.
- Samples from a subject or animal can be used in the present invention as obtained from the subject or animal, processed such as by sectioning, aspiration such as for bone marrow specimens or cultured such that cells from the sample can be sustained in vitro as a primary or continuous cell culture or cell line.
- Diagnosing such as in “diagnosing a neoplasm” refers to the determination of whether a subject comprises a disease or condition, such as a neoplasm including a malignancy or distinguishing one cancer from another.
- Prognosing such as “prognosing the course of a neoplasm” refers to the determination or prediction of the course of a disease or condition, such as a neoplasm including a malignancy.
- the course of a disease or condition can be prognosed, for example, based on life expectancy or quality of life.
- Prognosing includes the determination of the time course of a disease or condition, with or without a treatment or treatments. In the instance where treatment(s) are contemplated, the prognosing includes "prognosing the efficacy of a treatment for a neoplasm" or “prognosing a malignancy.”
- Modulates a neoplasm refers to the ability of a test compound, test chemical, bioactivity or bioactive compound to alter the growth and subsequent clinical course of a neoplasm. For example, a test compound can modulate a neoplasm by making the prognosis of the neoplasm better or worse in terms of life expectancy or quality of life.
- Modulates a malignancy refers to the ability of a test compound, test chemical, bioactivity or bioactive compound to alter the course of a malignancy. For example, a test compound can modulate a malignancy by making the prognosis of the malignancy better or worse in terms of life expectancy or quality of life.
- Prediction the efficacy of a treatment for a neoplasm refers to making a determination as to the efficacy of a test compound or pharmaceutical composition as at least a portion of a treatment for a neoplasm. Such a determination can be confirmed using a variety of methods, such as in vitro tests such as using cell culture models or in vivo tests, including animal models or human clinical trials.
- Prediction the efficacy of a treatment for a malignancy refers to making a determination as to the efficacy of a test compound or pharmaceutical composition as at least a portion of a treatment for a malignancy. Such a determination can be made or confirmed using a variety of methods, such as in vitro tests such as using cell culture models or in vivo tests, including animal models or human clinical trials.
- control or a “control sample” refers to a sample that acts as a positive or negative control as they are known in the art and as appropriate for a particular assay.
- a control can be performed contemporaneously with an assay or be performed at a prior or later time.
- the results of an assay can be compared to a control to determine the validity of the assay.
- Controls can also be used to produce standard curves such that the results of an assay can be semi-quantitative or quantitative in nature.
- the present invention recognizes that the type and preferably amount of transcription factors expressed in cells, particularly abnormal cells such as any neoplasm such as cancer cells, including myosarcomas and lymphomas, is related to the growth and/or differentiation state of such cells.
- the present inventors have discovered that this information can be usefully used in a variety of contexts, such as diagnosis and prognosis of a disease process or disease state, such as neoplasms such as cancer, and provides superior results to existing methods. Furthermore the methods may also be used for identifying compounds that are useful for treating disease process or disease states.
- the present invention includes several general and useful aspects, including:
- composition including at least two different specific binding members that can specifically bind with at least two different transcription factors
- a method of diagnosing a neoplasm such as a malignancy or prognosing the course of a neoplasm or malignancy or treatment thereof, including contacting at least one specific binding member that can specifically bind with a transcription factor with a sample, and detecting the binding of said specific binding member with a transcription factor in said sample;
- a method for identifying a test compound that modulates a neoplasm such as a malignancy including contacting a sample with at least one test compound, contacting said sample with at least one specific binding member that can bind with at least one transcription factor, and detecting the binding of said at least one specific binding member with at least one transcription factor;
- a method for predicting the efficacy of a treatment for a neoplasm such as a malignancy including: contacting a sample with at least one test chemical, at least one non-chemical treatment, or a combination thereof; contacting said sample with at least one specific binding member that can bind with a transcription factor; and detecting the binding of said at least one specific binding member with at least one transcription factor; 5) a method for distinguishing between clinically distinct subtypes of a type of neoplasm such as a malignancy including contacting at least one specific binding member that can specifically bind with a transcription factor with a sample, and detecting the binding of said at least one specific binding member with a transcription factor in said sample; and 6) a monoclonal antibody that can specifically bind with a member of the MyoD family of transcription factors, a leukemic transcription factor, a sex determination transcription factor or a hematopoiesis transcription factor.
- the present invention includes a composition including at least two different specific binding members that can specifically bind with at least two different transcription factors.
- the present invention includes a composition that includes at least two different specific binding members that can specifically bind with at least two different transcription factors.
- each specific binding member specifically binds to a single transcription factor.
- the composition can include between about two, about four, about six, about eight about ten, about thirty, about fifty, about seventy and about ninety different specific binding members and about three, about five, about seven, about nine about eleven about twenty, about forty, about sixty, about eighty and about one-hundred different specific binding members, preferably between about two and about ten specific binding members
- At least one of the specific binding members in the composition can be an antibody, such as a polyclonal antibody or a monoclonal antibody, or a portion, fragment, or active fragment thereof.
- the composition of the present invention can include at least one specific binding member that binds with a cellular component other than a transcription factor.
- the specific binding members can specifically bind with between about two, about four, about six, about eight about ten, about thirty, about fifty, about seventy and about ninety different transcription factors and about three, about five, about seven, about nine, about eleven about twenty, about forty, about sixty, about eighty and about one-hundred different transcription factors.
- the compositions of the present invention can be used as reagents to profile transcription factors presence and expression levels in a sample, such as a sample that includes at least one cell or a cell extract. Such profiling can include detecting at least one of the following: the type of transcription factors, the presence of transcription factors at a detectable level or the amount of a transcription factor.
- the composition of the present invention includes at least one specific binding member that can bind with a helix-loop-helix transcription factor or a basic helix-loop-helix transcription factor.
- the composition of the present invention includes specific binding members that can bind with between about two, about four, about six, about eight and about ten helix- loop-helix or basic helix-loop-helix transcription factors and about three, about five, about seven, about nine and about eleven helix-loop-helix or basic helix-loop-helix transcription factors.
- greater than ten, greater than twenty, greater than thirty, greater than forty, greater than fifty, greater than sixty such specific binding members are contemplated.
- compositions of the present invention can include specific binding members in a single container or provided in two or more separate containers.
- the separate containers can include one or more specific binding members.
- Myogenic Transcription Factors The present invention includes compositions that include at least one specific binding member wherein at least one specific binding member specifically binds with at least one myogenic transcription factor.
- the myogenic transcription factor is a member of the MyoD family of transcription factors, including, but not limited to myf5, MyoD, myogenin or myf6.
- Monoclonal antibodies of the present invention and those known in the art can be used in the present invention.
- the monoclonal antibody MyoDl 5.8 A was raised against mouse MyoDl , but detectably binds with human MyoD, and can be used in the present invention ( Dias et al., Cancer Res. 52:6431-6139 (1992); Wesche et al., Am. J. Surg. Pathol. 19:261-269 (1995); Tallini et al., Am. J. Pathol. 144:693-701 (1994); Parham et al., Acta Neuropathol (Berl.) 87:605- 611 (1994); Rosai et al., Am. J. Surg. Pathol. 15:974-981 (1991)).
- compositions that include at least one specific binding member wherein at least one specific binding member can specifically bind with at least one leukemic transcription factor.
- the at least one leukemic transcription factor is selected from the group consisting of E2A, PBX1, RBTN2, TC Ralpha/delta, PBX2, E2A, HLF, AML1, ETO, PML-RARalpha S, S/F forms, TEL, BCR, ABL, ALL, CBFb, DEK, CAN, c- MYC, TALI, TCRalpha, MST1, MST2, PU.l, Ikaros, E12, E47, E2-2, EBF, Pax5, ABF1, HES1, CBF, Ets 1, Wntl6, and chimeric proteins E2A/PBX1, RBTN2/TCRalpha/delata, E2A/PBX2, E2A/HLF, CBF ⁇ -MYHl l, A
- compositions that include at least one specific binding member wherein at least one specific binding member can specifically bind with at least one neurogenic transcription factor, such as NeuroDl, NeuroD2, NeuroD3 and those described in Littlewood and Evan, supra, 1998 and Lee et al., Science 268:836-844 (1995).
- at least one specific binding member can specifically bind with at least one neurogenic transcription factor, such as NeuroDl, NeuroD2, NeuroD3 and those described in Littlewood and Evan, supra, 1998 and Lee et al., Science 268:836-844 (1995).
- the present invention includes compositions that include at least one specific binding member wherein at least one specific binding member can specifically bind with at least one sex determination transcription factor, such as those described in Littlewood and Evan, supra, 1998.
- Hematopoiesis Transcription Factors The present invention includes compositions that include at least one specific binding member wherein at least one specific binding member can specifically bind with at least one hematopoiesis transcription factor, such as those described in Littlewood and Evan, supra, 1998.
- the present invention also includes compositions where at least one the specific binding members is immobilized, reversibly immobilized, irreversibly immobilized or both, on a solid support.
- These compositions are useful for the performance of specific binding reactions on appropriate solid supports, such as immunoassays, such as (enzyme linked immuno sorbent assays (ELISAs), western blots, immunocyhtochemistry, immunohistochemistry and immunochromatographic assays as they are known in the art.
- the immobilized specific binding member can be unbound with its specific binding partner transcription factor, or be bound with its specific binding partner transcription factor.
- Such solid supports can be used in a wide variety of specific binding formats, many of which use detectably labeled specific binding reagents, such as detectably labeled antibodies or antigens.
- Such formats are represented by the following: Direct non-competitive assay on a solid support (U.S. Patent Nos. 4,187,075 and 4,497,900); Competitive binding of a solid support (U.S. Patent Nos. 4,134,792, 3,654,090, 4,478,946, 4,092,408, 4,478,946, , 4,271,140, 4,288,237, 4,490,473, 4,243,749, 4,298,685, 3,839,153, 4,048,298, 4,271,140; Sequential saturation (U.S. Patent Nos.
- the present invention also includes composition where at least one specific binding members such as an antibody of the present invention or active fragment thereof is detectably labeled.
- Specific binding members can be detectably labeled with detectable labels appropriate for a particular assay format (see, for example, Harrow, supra, 1988).
- the different specific binding members can be detectably labeled with the same or different detectable label.
- different specific binding members are labeled with different detectable labels that can be distinguished using a method of the present invention.
- the different labels can be different classes of labels, such as a fluorophore and a radiolabel, or can be distinguishable types of a class of label, such as different fluorophores, such as rhodamine, FITC,
- the present invention also includes specific binding members, either immobilized or not immobilized, wherein at least one of the specific binding members is bound with a transcription factor.
- the specific binding member can be bound with a transcription factor in any environment, such as in a biological sample, in a tissue from an organism such as a mammal, in a cell such as a eukaryotic cell including a mammalian cell, from an extract of a tissue or from an extract of a cell.
- the present invention includes compositions where at least one of the specific binding members is bound with a transcription factor in at least one cell or in a tissue sample.
- the at least one cell can be from any source, including a biological sample, such as a fluid or from a tissue, or can be a cell in culture.
- this aspect of the invention uses immunocytochemistry and immunohistochemistry as such methods are known in the art.
- the cells are fixed or permeabilized with an appropriate reagent, such as methanol, acetone, glutaraldehyde, formaldehyde or paraformadehyde, such that specific binding members, such as antibodies, can bind with transcription factors within the cells.
- the binding of the specific binding member with a transcription factor can be detected using a variety of methods such as they are known in the art for a particular label.
- radioactive labels can be detected using autoradiography and fluorescent labels can be detected using fluorescent detection methods.
- Enzyme labels that produce chromogens or chemiluminescence upon action of an appropriate substrate can also be used.
- the detection methods can include direct and indirect binding reactions that use, for example, fluorescent labels.
- compositions of the present invention include cells in which a specific binding member is bound with a transcription factor in, or derived from a wide variety of cells, samples or tissues.
- cells refers to mammalian cells of any type, including cells derived from tissues taken from a subject or a portion thereof or cells in culture.
- Cells taken from a subject or a portion thereof can be from any appropriate fluid, tissue or organ.
- the fluid, tissue or organ can be a normal sample or an abnormal sample.
- the cell can be a malignant cell, and can be from a child or an adult.
- the malignant cell can be a soft tissue malignant cell or a solid malignant cell.
- the malignant cell can be a sarcoma cell, including a myosarcoma cell or rhabdomyosarcoma cell, including an alveolar rhabdomyosarcoma and/or an embryonal rhabdomyosarcoma.
- the malignant cell can also be of epithelial cell malignancies, leukemias or lymphomas, or solid bone tumors.
- the present invention also includes a method of diagnosing a neoplasm such as a malignancy or prognosing the course of a neoplasm such as a malignancy or treatment thereof including contacting at least one specific binding member that can specifically bind with a transcription factor with a sample, and detecting the binding of said specific binding member with a transcription factor in said sample.
- a method of diagnosing a neoplasm such as a malignancy including: contacting a composition at least one specific binding member that can specifically bind with a transcription factor with a sample, and detecting the binding of said specific binding member with a transcription factor in said sample.
- the method uses a composition of the present invention that includes a pool of at least two specific binding members that specifically bind with at least two different transcription factors.
- a sample is contacted with a composition that includes at least one specific binding member (such as an antibody) that specifically binds with a transcription factor.
- the composition is a composition of the present invention.
- the binding of the at least one specific binding member to a transcription factor in the sample can be detected using a variety of methods as they are known in the art and disclosed herein, such as direct or indirect detection methods.
- a specific binding member, such as an antibody can be detectably labeled such that the binding of the specific binding member to a transcription factor can be directly determined.
- the binding of a specific binding member to a transcription factor can be determined by indirect methods, such as using a detectably labeled antibody that binds with a specific binding member.
- the detectable presence, absence, type or amount of transcription factors in a sample can be determined using this method.
- the relative detectable presence, absence, type or amount of transcription factors in a sample can provide a profile of transcription factors in the sample.
- the profile of one or more transcription factors in a sample can be used as a diagnostic for neoplasms such as malignancies.
- the detectable presence, absence, type or amount of transcription factors in a sample can be compared to such a profile for a variety of cell types such as normal cells or neoplastic cells, such as malignant cells.
- cells can also be profiled, including normal or non-normal (such as neoplasms or malignancies) cells from a variety of tissues, fluids or organs from adult, adolescent, youth, progeny or children, newborns, fetus or embryo at any stage of development of a variety of animals, including humans.
- normal or non-normal such as neoplasms or malignancies
- the profiles of such cells can be used to determine the developmental status of a cell in the continuum between embryonic stem cells and terminally differentiated cells because the profile of transcription factors along that profile are different and characteristic of stages of development.
- primitive mesodermal cells multipotential embryonal cells
- myoblasts myogenically committed proliferative stem cells
- Myoblasts have members of MyoD family induced, such as Myf-5, MyoD and myogenin.
- Myoblasts fuse with each other to form myotubes (bi- or multinucleated syncytia) with an up-regulation of members of the MyoD family such as MyoD and myogenin.
- Myotubes differentiate to myofibre (basic unit of mature muscle) with an up-regulation of MRF4 and a down-regulation of MyoD, Myf-5 and myogenin (see, Dias et al., Seminars in Diagnostic Pathology 11 :3-14 (1994)).
- Differentiation profiles of other types of cells, such as white blood cells, are also characterized (Roitt et al., Immunology, Third Ed., Mosby, St. Louis (1993)).
- the present invention includes these recited cell types and all cell types, including those of mesodermal, ectodermal and endodermal origin that have a differentiation profile.
- Profiles of transcription factors in these cells along a differentiation pathway can be used as controls, both positive and negative, in order to compare the profile of transcription factors of a sample being analyzed using the methods of the present invention.
- Such controls can be performed at the same or different time as the sample being analyzed.
- the present invention also includes a method of prognosing the course of a neoplasm such as a malignancy, including: contacting at least one specific binding member that specifically bind with a transcription factor with a sample, and detecting the binding of said at least one specific binding member with a transcription factor in said sample.
- the method uses a composition of the present invention that includes at least one specific binding member that specifically bind with at least two different transcription factors.
- a sample is contacted with a composition that includes at least one specific binding member (such as an antibody) that specifically binds with a transcription factor.
- the composition is a composition of the present invention.
- the binding of the at least one specific binding member to a transcription factor in the sample can be detected using a variety of methods as they are known in the art and disclosed herein, such as direct or indirect detection methods.
- a specific binding member such as an antibody
- the binding of a specific binding member to a transcription factor can be determined by indirect methods, such as using a detectably labeled antibody that binds with a specific binding member.
- the detectable presence, absence, type or amount of transcription factors in a sample can be determined using this method.
- the relative detectable presence, absence, type or amount of transcription factors in a sample can provide a profile of transcription factors in the sample.
- the profile of one or more transcription factors in a sample can be used as for prognosing the course of a neoplasm such as a malignancy.
- the detectable presence, absence, type or amount of transcription factors in a sample can be compared to such a profile for a variety of cell types, such as normal cells or neoplastic cells such as malignant cells.
- Other types of cells can also be profiled, including normal or non-normal cells from a variety of tissues, fluids or organs from adult, adolescent, youth, progeny or children, newborns, fetus or embryo at any stage of development of a variety of animals, including humans.
- the profiles of such cells can be used to determine the developmental status of a cell in the continuum between embryonic stem cells and terminally differentiated cells because the profile of transcription factors along that profile are different and characteristic of stages of development.
- primitive mesodermal cells differentiate to myoblasts, myotubes and myofibre while various members of the MyoD family of transcription factors are up- or down-regulated (see, Dias et al., Seminars in Diagnostic Pathology, 11 :3-14 (1994).
- Differentiation profiles of other types of cells, such as while blood cells are also characterized (Roitt et al., Immunology, Third Ed., Mosby, St. Louis (1993)).
- the present invention includes these recited cell types and all cell types, including those of mesodermal, ectodermal and endodermal origin that have a differentiation profile.
- Profiles of transcription factors in these cells along a differentiation pathway can be used as controls, both positive and negative, in order to compare the profile of transcription factors of a sample being analyzed using the methods of the present invention.
- Such controls can be performed at the same or different time as the sample being analyzed.
- the transcription factor profile of a sample can be compared to controls to determine the stage of a disease process, such as a neoplasm such as a malignancy, because the transcription factor profile of a sample having a disease process that may change over time.
- the stage of disease process is related to its expected course in terms of, for example, life expectancy or quality of life.
- the results of the present invention can be used to prognose the course of a disease process, such as a malignancy.
- the present invention includes a method of prognosing the efficacy of a treatment for a neoplasm such as a malignancy, comprising: contacting at least one specific binding member that can specifically bind with a transcription factors with a sample, and detecting the binding of said specific binding member with a transcription factor in said sample.
- the method uses a composition of the present invention that includes at least two specific binding members that specifically bind with at least two different transcription factors.
- a sample is contacted with a composition that includes at least one specific binding member (such as an antibody) that specifically binds with a transcription factor.
- the composition is a composition of the present invention.
- the binding of the at least one specific binding member to a transcription factor in the sample can be detected using a variety of methods as they are known in the art and disclosed herein, such as direct or indirect detection methods.
- a specific binding member, such as an antibody can be detectably labeled such that the binding of the specific binding member to a transcription factor can be directly determined.
- the binding of a specific binding member to a transcription factor can be determined by indirect methods, such as using a detectably labeled antibody that binds with a specific binding member.
- the detectable presence, absence, type or amount of transcription factors in a sample can be determined using this method.
- the relative detectable presence, absence, type or amount of transcription factors in a sample can provide a profile of transcription factors in the sample.
- the profile of one or more transcription factors in a sample can be used to prognose the efficacy of a treatment for a neoplasm such as a malignancy.
- the detectable presence, absence, type or amount of transcription factors in a sample can be compared to such a profile for a variety of cell types, such as normal cells or neoplastic cells such as malignant cells.
- Other types of cells can also be profiled, including normal or non-normal cells from a variety of tissues, fluids or organs from adult, adolescent, youth, progeny or children, newborns, fetus or embryo at any stage of development of a variety of animals, including humans.
- the profiles of such cells can be used to determine the developmental status of a cell in the continuum between embryonic stem cells and terminally differentiated cells or tissues because the profile of transcription factors along that profile or pathway are different and characteristic of stages of development.
- mesodermal cells differentiate to myoblasts, myotubes and myofibre while various members of the MyoD family of transcription factors are up- or down- regulated (see, Dias et al., Seminars in Diagnostic Pathology, 11 :3-14 (1994).
- Differentiation profiles of other types of cells such as while blood cells, are also characterized (Roitt et al., Immunology, Third Ed., Mosby, St. Louis (1993)).
- the present invention includes these recited cell types and all cell types, including those of mesodermal, ectodermal and endodermal origin that have a differentiation profile.
- Profiles of transcription factors in these cells along a differentiation pathway can be used as controls, both positive and negative, in order to compare the profile of transcription factors of a sample being analyzed using the methods of the present invention.
- Such controls can be performed at the same or different time as the sample being analyzed.
- the transcription factor profile of a sample can be compared to controls to determine the type of a disease process or the stage of a disease process, such as a neoplasm such as a malignancy, because the transcription factor profile of a sample having a disease process may change over the course of the disease process and are characteristic of a disease process.
- the stage of disease process is related to its expected course in terms of, for example, response to treatments, such as radiotherapy, chemotherapy or combinations thereof.
- the results of the present invention can be used to prognose the efficacy of a treatment directed towards a disease process, such as a neoplasm such as a malignancy.
- the present invention also includes method for identifying a test compound or therapy that modulates a neoplasm such as a malignancy including: contacting a sample with at least one test compound or at least one test therapy or a combination thereof, contacting said sample with at least one specific binding member that can bind with at least one transcription factor, and detecting the binding of said at least one specific binding member with at least one transcription factor.
- a method for identifying a test compound that modulates a neoplasm such as a malignancy comprising: contacting a sample with at least one test compound at least one test therapy or a combination thereof; contacting said sample with at least one specific binding member that can bind with at least one transcription factor; and detecting the binding of said at least one specific binding member with at least one transcription factor.
- the method uses a composition of the present invention that includes at least two specific binding members that specifically bind with at least two different transcription factors.
- the binding of a specific binding member to a transcription factor can be determined by indirect methods, such as using a detectably labeled antibody (or a second binding member that is labeled, such as streptavidin that is labeled with a fluorochrome or enzyme that binds with a biotinylated primary antibody) that binds with a specific binding member.
- a detectably labeled antibody or a second binding member that is labeled, such as streptavidin that is labeled with a fluorochrome or enzyme that binds with a biotinylated primary antibody
- Other types of cells can also be profiled, including normal or non-normal cells from a variety of tissues, fluids or organs from adult, adolescent, youth, progeny or children, newborns, fetus or embryo at any stage of development of a variety of subjects, including animals and humans.
- the profiles of such cells can be used to determine the developmental status of a cell in the continuum between embryonic stem cells and terminally differentiated cells because the profile of transcription factors along that profile are different and characteristic of stages of development.
- test compound The structure of a test compound can be determined or confirmed by methods known in the art, such as mass spectroscopy. For test compounds stored for extended periods of time under a variety of conditions, the structure, activity and potency thereof can be confirmed. Identified test compounds can be evaluated for a particular activity using art-recognized methods and those disclosed herein. For example, if an identified test compounds is found to have anticancer cell activity in vitro, then the test compound would have presumptive pharmacological properties as a chemotherapeutic to treat cancer. Such nexuses are known in the art for several disease states, and more are expected to be discovered over time. Based on such nexuses, appropriate confirmatory in vitro and in vivo models of pharmacological activity, and toxicology, and be selected and performed. The methods described herein can also be used to assess pharmacological selectivity and specificity, and toxicity.
- Profiles of transcription factors in these cells along a differentiation pathway can be used as controls, both positive and negative, in order to compare the profile of transcription factors of a sample being analyzed using the methods of the present invention.
- Such controls can be performed at the same or different time as the sample being analyzed.
- the transcription factor profile of a sample can be compared to controls, including the transcription factor profile of the sample prior to being contacted with a test compound, to determine the responsiveness of the sample to a test compound or test treatment or combination thereof.
- a test compound or test treatment or combination thereof will alter the transcription profile of a sample from a less differentiated state to a more differentiated state, but the reverse may also be true.
- Compounds or treatments or combinations thereof that can promote transcription factor profiles that are indicative of a more differentiated state have presumptive therapeutic activity as anti-neoplastic agents or treatments, particularly for neoplasms that are characterized as being in the form of a less differentiated state.
- Different subjects and different neoplasms have different responsiveness to a variety of pharmaceutical compositions.
- a pharmaceutical composition that has a relatively high likelihood of success can be preselected prior to administering of potentially damaging or ineffective compounds to a subject.
- the amount of pharmaceutical composition or treatment or combination thereof effective to cause a shift in transcription factor profiles from a less differentiated state to a more differentiated state can be determined by using a variety of concentrations of a pharmaceutical composition or treatment or combination thereof in this method.
- pharmaceutical compositions that include a plurality of pharmaceutical agents can be evaluated using this method.
- pharmaceutical compositions that are not or have not been considered useful as a treatment for a disease state, such as a neoplasm such as a malignancy can be evaluated using this method.
- new uses for existing pharmaceutical compositions can be identified using the methods of the present invention.
- the present invention also includes pharmaceutical compositions or treatments or combinations thereof identified by this method.
- the compound or treatment or combination thereof if appropriate, can be provided in a pharmaceutically acceptable carrier.
- the compound or treatment or combination thereof identified by this method if appropriate, can be a pharmaceutical composition and provided in an appropriate form, dose, pharmaceutically acceptable carrier and/or container or packaging.
- Such container or packaging can include appropriate instructions for the administration of the pharmaceutical composition or therapy or combination thereof including route of administration, dose, regime and related precautions.
- Hybridoma cells that produced anti-MyoD antibodies are identified using solid-phase immunoassays that use the purified MyoD as an immobilized antigen and clonal populations of these hybridomas are produced and maintained (see, for example, Wesche et al., Am. J. Surg. Pathol. 19:261-269 (1995); Tallini et al., Am. J. Pathol 144:693-701 (1994); Parham et al., Acta Neuropathol. (Berl.) 87:605-611 (1994); Rosai et al., Am. J. Surg. Pathol. 15:974-981 (1991)).
- Some antibody preparations are highly specific for native MyoD using extracts of a panel of small round cell tumor cell lines and western blotting of cell lysates.
- Monoclonal antibody 12 detectably binds with doublet bands corresponding to the molecular size of MyoD for the lysate from Rh30 rhabdomyosarcoma cell line but does not detectably bind with lysates from the primitive neuroectodermal tumor cell line PFSK-1 A, Burkitt' s lymphoma cell line EB-2, neuroblastoma cell line SKNSH and Ewing sarcoma cell line SJSA-1.
- Immunohistochemical Staining detectably binds with doublet bands corresponding to the molecular size of MyoD for the lysate from Rh30 rhabdomyosarcoma cell line but does not detectably bind with lysates from the primitive neuroectodermal tumor cell line PFSK-1 A, Burkitt' s lymphoma cell
- Some monoclonal antibodies stain the nuclei of the rhabdomyosarcoma cells RD, Rh28 and Rh30. Some monoclonal antibodies stain the nuclei of primary cultures from normal human muscle (NHMB). Monoclonal antibodies that do not detectably stain the normal human myoblasts also do not detectably stain native MyoD as can be determined by western blotting. The myoblast cell line L6 does not express MyoD and can be used as control cell line.
- Twenty samples containing small round cell neoplasms were provided by a clinical entity (Los Angeles Children's Hospital) that had diagnosed five of those twenty samples as rhabdomyosarcoma, five as primitive neuroectodermal tumors, five as Ewing's sarcoma and five as non-Hodgkin's lymphoma by visual determination. The samples were provided for testing in a blind configuration.
- the samples were stained with monoclonal antibody 12.
- the results of the monoclonal staining conflicted with the visual diagnosis in two of the twenty samples. Table I summarizes these results.
- the present inventors noted that some of tumors that were diagnosed by the clinical entity as rhabdomyosarcoma detectably stained with the anti-MyoD monoclonal antibody 12. None of five lymphomas and none of the five primitive neuroectodermal tumors detectably stained with the anti-MyoD monoclonal antibody.
- the one MyoD negative tumor was subsequently found to be desmin negative. It was initially diagnosed as a metastatic undifferentiated malignant tumor. Electron micrograph studies suggested a tumor with a biphenotypical differentiation. Staining with anti-MyoD and anti-desmin indicate that it is not a rhabdomyosarcoma and that it did not have a myogenic component.
- the second conflicting sample had been diagnosed by the clinical entity as a Ewing's sarcoma but stained strongly with an anti-MyoD monoclonal antibody 12. Subsequent staining with an anti-desmin antibody supported the diagnosis of rhabdomyosarcoma of the present invention.
- Ewing's sarcoma can be confirmed using PCR reactions because Ewings sarcomas and primitive neuroectodermal tumors are characterized by the t(l 1 :22) chromosome translocation which leads to the juxtapositioning of a gene designated EWS on chromosome 22 with members of the ETS gene family.
- Example 5 Staining of fixed tumor tissues Twenty-one paraffin-embedded tumors were stained with anti-MyoD monoclonal antibody 12. Seven of seven rhabdomyosarcoma detectably stained with that monoclonal antibody while fourteen of fourteen non-rhabdomyosarcoma tumors, including non-Hodgkins lymphomas, neuroblastomas and Ewings sarcomas did not detectably stain with that monoclonal antibody.
- a monoclonal antibody to myogenin (designated F5D, available from Imgenex and Pharmagen) that recognizes amino acid residues 144 to 158 of myogenin and detectably binds with human, mouse and cat myogenin by western blotting and immuno histochemical staining was used for these studies (Wright et al., Mol. Cell. Biol. 11 :4104-4110 (1991); Wang et al., Am.
- Example 7 Monoclonal antibodies that specifically bind with myf5 Monoclonal antibodies that specifically bind with myf5 can be made using the general methods described in Example 1 through Example 6. One method of making and identifying such monoclonal antibodies is provided below.
- Antigens used as an immunogen to raise and as an antigen to screen for monoclonal antibodies that specifically bind with myf5 are derived from KLH-conjugated myf5 derived peptides and recombinant myf5 fusion proteins.
- KLH-conjugated human myf5 (hmyf5) is made by synthesizing a peptide that is specific for myf5, such as the sequence amino terminus- EDEDSGQLEAKHAGCH-carboxy terminus (SEQ ID NO:l) and conjugating that peptide to KLH using established procedures.
- the KLH-conjugated myf5 peptide is used as an immunogen to raise splenocytes that are fused with Fo-SF-II myeloma cells to generate hybridomas generally following established methods.
- Supernatants from the hybridomas are initially screened for detectable binding with recombinant MyoD (myO), myogenin (myf4), myf5 and myf6 (MRF4). Only hybridomas producing antibodies that detectably bound with myf5 but not the other members of the MyoD family are selected for further testing.
- Supernatants produced by the selected hybridomas are evaluated for detectable binding with unconjugated recombinant myf5 peptide (SEQ ID NO:l).
- Example 8 Monoclonal antibodies that specifically bind with myf ⁇
- the myf ⁇ expression vector can encode the entire myf ⁇ cDNA whose expression is under the control of a viral long terminal repeat (LTR). Only antibodies that detectably bound with the myf ⁇ -transfected cells by immunohistochemistry and by western blotting using cell lysates from the myf ⁇ -transfected cells are selected for further study.
- LTR viral long terminal repeat
- the further selected antibodies are screened for detectable binding against a large number of small round cell tumor cell lines.
- Antibody preparations that detectably bind with myf ⁇ expressing cells are selected as potential diagnostic reagents.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU11889/01A AU1188901A (en) | 1999-09-24 | 2000-09-23 | Compositions and methods for improved detection and classification of neoplasms |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15597299P | 1999-09-24 | 1999-09-24 | |
US60/155,972 | 1999-09-24 | ||
US09/499,559 US6623936B1 (en) | 1999-09-24 | 2000-02-07 | Compositions and methods for improved detection and classification of neoplasms |
US09/499,559 | 2000-02-07 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001021136A2 true WO2001021136A2 (en) | 2001-03-29 |
WO2001021136A3 WO2001021136A3 (en) | 2001-10-04 |
WO2001021136A9 WO2001021136A9 (en) | 2001-11-08 |
Family
ID=26852758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/026105 WO2001021136A2 (en) | 1999-09-24 | 2000-09-23 | Compositions and methods for improved detection and classification of neoplasms |
Country Status (3)
Country | Link |
---|---|
US (1) | US6623936B1 (en) |
AU (1) | AU1188901A (en) |
WO (1) | WO2001021136A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003073105A2 (en) * | 2002-02-28 | 2003-09-04 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of plag1 and plagl2 in cancer diagnosis and drug screening |
US7812124B2 (en) | 2000-11-16 | 2010-10-12 | Kaia Palm | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
WO2011097533A1 (en) | 2010-02-04 | 2011-08-11 | Transmolecular, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
CN102925558A (en) * | 2012-09-29 | 2013-02-13 | 童永清 | Kit for detecting mRNA expression level of PML-RARa fusion gene |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666421A (en) | 1971-04-05 | 1972-05-30 | Organon | Diagnostic test slide |
EP0063810B1 (en) | 1981-04-29 | 1986-03-05 | Ciba-Geigy Ag | New devices and kits for immunological analysis |
US4468371A (en) | 1982-07-19 | 1984-08-28 | Daryl Laboratories, Inc. | Immunoassay test slide |
US4591570A (en) | 1983-02-02 | 1986-05-27 | Centocor, Inc. | Matrix of antibody-coated spots for determination of antigens |
US5866350A (en) | 1985-03-19 | 1999-02-02 | Helen Hwai-An Lee | Method for the immunological determination of a biological material in a sample |
US4880750A (en) | 1987-07-09 | 1989-11-14 | Miragen, Inc. | Individual-specific antibody identification methods |
GB8803000D0 (en) | 1988-02-10 | 1988-03-09 | Ekins Roger Philip | Determination of ambient concentrations of several analytes |
US5340739A (en) * | 1988-07-13 | 1994-08-23 | Brigham & Women's Hospital | Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof |
US5223220A (en) | 1990-03-27 | 1993-06-29 | Pacific Biotech, Inc. | Solid phase immunoassay device and method of making same |
US5885769A (en) | 1991-02-14 | 1999-03-23 | Schering Corporation | Screening systems |
US5244788A (en) | 1992-07-01 | 1993-09-14 | Hubscher Thomas T | Method and apparatus for performing determinations of immune rectants in biological fluids |
US5824770A (en) | 1992-09-14 | 1998-10-20 | The General Hospital Corporation | Ikaros polypeptides |
US5688918A (en) | 1993-08-02 | 1997-11-18 | Health Research, Inc. | p53as protein and antibody therefor |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5763198A (en) | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5876949A (en) | 1995-05-31 | 1999-03-02 | The Trustees Of The University Of Pennsylvania | Antibodies specific for fragile X related proteins and method of using the same |
US5858682A (en) | 1996-08-02 | 1999-01-12 | Pharmingen | E2A/pbx1 fusion protein specific monoclonal antibodies |
US5858801A (en) | 1997-03-13 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Patterning antibodies on a surface |
-
2000
- 2000-02-07 US US09/499,559 patent/US6623936B1/en not_active Expired - Fee Related
- 2000-09-23 AU AU11889/01A patent/AU1188901A/en not_active Abandoned
- 2000-09-23 WO PCT/US2000/026105 patent/WO2001021136A2/en active Application Filing
Non-Patent Citations (3)
Title |
---|
KABLAR ET AL.: 'MyoD and Myf-5 differentially regulate the development of limb versus trunk skeletal muscle' DEVELOPMENT vol. 124, 1997, pages 4729 - 4738, XP002940333 * |
MIYAMOTO ET AL.: 'Helix-loop-helix proteins LYL1 and E2a form heterodiceric complexes with distinctive DNA-binding properties in hematolymphoid cells' MOLECULAR AND CELLULAR BIOLOGY vol. 16, no. 5, May 1996, pages 2394 - 2401, XP002940331 * |
TONIN ET AL.: 'Muscle-specific gene expresion in rhabdomyosarcomas and stages of human fetal skeletal muscle development' CANCER RESEARCH vol. 51, October 1991, pages 5100 - 5106, XP002940332 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7812124B2 (en) | 2000-11-16 | 2010-10-12 | Kaia Palm | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
WO2003073105A2 (en) * | 2002-02-28 | 2003-09-04 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of plag1 and plagl2 in cancer diagnosis and drug screening |
WO2003073105A3 (en) * | 2002-02-28 | 2004-04-01 | Vlaams Interuniv Inst Biotech | Use of plag1 and plagl2 in cancer diagnosis and drug screening |
WO2011097533A1 (en) | 2010-02-04 | 2011-08-11 | Transmolecular, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
CN102925558A (en) * | 2012-09-29 | 2013-02-13 | 童永清 | Kit for detecting mRNA expression level of PML-RARa fusion gene |
Also Published As
Publication number | Publication date |
---|---|
WO2001021136A9 (en) | 2001-11-08 |
WO2001021136A3 (en) | 2001-10-04 |
US6623936B1 (en) | 2003-09-23 |
AU1188901A (en) | 2001-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7479371B2 (en) | Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor | |
US20170114415A1 (en) | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy | |
CA2488404A1 (en) | Genes and polypeptides relating to human colon cancers | |
WO2006073195A1 (en) | Method for predicting or diagnosing diabetes and kit for predicting or diagnosing diabetes | |
JPH08508396A (en) | Nuclear matrix protein | |
US6623936B1 (en) | Compositions and methods for improved detection and classification of neoplasms | |
CA2662012C (en) | Boris isoforms and methods of detecting and treating disease | |
US20170138958A1 (en) | Method for measuring anti-wt1 antibody | |
EP1172654B1 (en) | Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors | |
CN109633165B (en) | Application of anti-HSPA 4 autoantibody as breast cancer diagnosis or prognosis evaluation marker | |
WO2001085762A2 (en) | Cancer diagnosis and assays for screening anti-cancer agents | |
US20050266399A1 (en) | HCV regulated protein expression | |
US7622264B2 (en) | Methods for screening for modulators of CXCR3 signaling | |
EP0582477A1 (en) | Method for diagnosing cancer and pharmaceutical composition | |
US8399202B2 (en) | Peptides for development of diagnostic and therapeutic agents and methods of using same | |
CN115112889A (en) | Application of antigen combination in preparation of lung cancer detection reagent or kit | |
WO2023061388A1 (en) | Immunoassay of galectin-3 | |
US20060135750A1 (en) | Novel protein and gene encoding the same | |
KR20010077769A (en) | Anti-human mitochondrial adenylate kinase isozyme antibody, diagnostic formulation and diagnositc kit for cardiac disease | |
KR101901457B1 (en) | Novel Biomarkers for Liver Cancer Based on Liver Cancer Stem Cell Characteristics and Uses thereof | |
JP5750646B2 (en) | Test method for allergic diseases by measuring SCCA2 concentration | |
KR20080028642A (en) | Protein marker endorepellin lg3 fragment for breast cancer diagnosis and diagnosis kit for breast cancer using antibody against the same | |
WO2006119887A1 (en) | Aminopeptidase n as target/marker for insulin resistance | |
WO2005094422A2 (en) | Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases | |
KR101297667B1 (en) | Peptides targeting the bcl-2 protein and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |